DISTINCT BIOMARKERS ENRICH FOR CLINICAL RESPONSE TO TOCILIZUMAB (TCZ) AND ADALIMUMAB (ADA) IN ADACTA: A HEAD-TO-HEAD MONOTHERAPY STUDY IN PATIENTS (PTS) WITH METHOTREXATE (MTX)-IR RHEUMATOID ARTHRITIS (RA)

被引:0
|
作者
Herman, A. [1 ]
Musselman, D. [1 ]
Fischer, S. [1 ]
Setiadi, A. [1 ]
Gabay, C. [2 ]
Kavanaugh, A. [3 ]
Klearman, M. [1 ]
Song, A. [1 ]
Townsend, M. [1 ]
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] U Hosp Geneva, Geneva, Switzerland
[3] U Calif, San Diego, CA USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:206 / 206
页数:1
相关论文
共 25 条
  • [1] CHANGES IN LIPOPROTEIN(A) AFTER TREATMENT WITH TOCILIZUMAB (TCZ), ADALIMUMAB (ADA), AND METHOTREXATE (MTX) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
    Gabay, C.
    McInnes, I.
    Kavanaugh, A.
    Tuckwell, K.
    Collinson, N.
    Klearman, M.
    Green, J.
    Sattar, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 124 - 124
  • [2] AUSTRALIAN ECONOMIC EVALUATION OF TOCILIZUMAB (TCZ) MONOTHERAPY VS. ADALIMUMAB (ADA) MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) BASED ON THE ADACTA TRIAL
    Ngo, P.
    Sorathia, R.
    Todd, C.
    Jones, G.
    Nash, P.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 : 12 - 12
  • [3] COMPARATIVE COST PER RESPONSE FOR FOUR CLINICAL OUTCOMES OF TOCILIZUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN A HEAD-TO-HEAD RANDOMISED DOUBLE-BLIND SUPERIORITY TRIAL (ADACTA) IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Best, J.
    Pei, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 521 - 521
  • [4] Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
    Jennie H. Best
    Steven C. Vlad
    Jinglan Pei
    [J]. Rheumatology and Therapy, 2020, 7 : 165 - 171
  • [5] Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
    Best, Jennie H.
    Vlad, Steven C.
    Pei, Jinglan
    [J]. RHEUMATOLOGY AND THERAPY, 2020, 7 (01) : 165 - 171
  • [6] Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA)
    Strand, Vibeke
    Lampl, Kathy
    Birchwood, Christine
    Pei, Jinglan
    Tuckwell, Katie
    Finch, Rebecca
    Gabay, Cem
    Kavanaugh, Arthur
    Jones, Graeme
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] Tocilizumab (TCZ) Monotherapy is Superior to Adalimumab (ADA) Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis (RA): 24-Week Data from the Phase 4 ADACTA Trial
    Baminger, H.
    [J]. JOURNAL FUR MINERALSTOFFWECHSEL, 2012, 19 (03): : 138 - 138
  • [8] TOCILIZUMAB (TCZ) MONOTHERAPY IS SUPERIOR TO ADALIMUMAB (ADA) MONOTHERAPY IN REDUCING DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): 24-WEEK DATA FROM THE PHASE 4 ADACTA TRIAL
    Gabay, C.
    Emery, P.
    van Vollenhoven, R.
    Dikranian, A.
    Alten, R.
    Klearman, M.
    Musselman, D.
    Agarwal, S.
    Green, J.
    Kavanaugh, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 152 - 152
  • [9] The AMBITION study: Superiority of tociluzumab (TCZ) vs methotrexate (MTX) monotherapy in patients with rheumatoid arthritis (RA)
    Jones, G.
    Gu, J. R.
    Lowenstein, M.
    Calvo, A.
    Gomez-Reino, J. J.
    Siri, D.
    Tomsic, M.
    Blackburn, R.
    Woodworth, T.
    Sebba, A.
    Genovese, M.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S618 - S618
  • [10] LONG-TERM EFFICACY AND SAFETY OF TOCILIZUMAB (TCZ) MONOTHERAPY IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) PREVIOUSLY METHOTREXATE (MTX) NAIVE OR MTX FREE FOR 6 MONTHS PRIOR TO STUDY START
    Jones, G.
    Sebba, A.
    Anisfeld, A.
    Devenport, J.
    Bernasconi, C.
    Smart, D.
    Galindez, D.
    Mpofu, C.
    Gomez-Reino, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 457 - 458